Skip to main content
SpringerLink
Log in
Book cover

PET/CT in Melanoma pp 15–23Cite as

Management of Melanoma

  • Chapter
  • First Online:

  • 588 Accesses

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

Until recently, there have been few effective treatment options for patients with metastatic melanoma. A number of targeted therapies and immune-modulating therapies have dramatically improved outcomes and changed paradigms of management. For patients with early stage disease, surgery remains the primary form of management.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163:238–56.

    Article  CAS  PubMed  Google Scholar 

  2. Park KG, Blessing K, Kernohan NM. Surgical aspects of subungual malignant melanomas. The Scottish Melanoma Group. Ann Surg. 1992;216:692–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Moehrle M, Metzger S, Schippert W, et al. “Functional” surgery in subungual melanoma. Dermatol Surg. 2003;29:366–74.

    PubMed  Google Scholar 

  4. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg. 2002;89:1223–7.

    Article  CAS  PubMed  Google Scholar 

  5. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.

    Article  CAS  PubMed  Google Scholar 

  6. Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg. 2002;137:1101–5.

    PubMed  Google Scholar 

  7. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol. 2001;8:101–8.

    CAS  PubMed  Google Scholar 

  8. Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757–66.

    Article  CAS  PubMed  Google Scholar 

  9. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.

    Article  CAS  PubMed  Google Scholar 

  11. Gaudy C, Richard MA, Folchetti G, et al. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg. 2006;10:115–21.

    Article  PubMed  Google Scholar 

  12. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg. 1995;21:285–90.

    CAS  PubMed  Google Scholar 

  13. Hayes AJ, Clark MA, Harries M, Thomas JM. Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg. 2004;91:673–82.

    Article  CAS  PubMed  Google Scholar 

  14. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196–201.

    Article  CAS  PubMed  Google Scholar 

  15. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195–205.

    Article  PubMed  Google Scholar 

  16. Thompson JF, Kam PC. Current status of isolated limb infusion with mild hyperthermia for melanoma. Int J Hyperth. 2008;24:219–25.

    Article  CAS  Google Scholar 

  17. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000;7:160–5.

    Article  CAS  PubMed  Google Scholar 

  18. Stevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer. 2000;88:88–94.

    Article  CAS  PubMed  Google Scholar 

  19. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) study 96.06. Radiother Oncol. 2006;81:136–42.

    Article  PubMed  Google Scholar 

  20. Conill C, Jorcano S, Domingo-Domenech J, et al. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res. 2007;17:304–9.

    Article  CAS  PubMed  Google Scholar 

  21. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.

    CAS  PubMed  Google Scholar 

  22. Wheatley K, Ives NJ, Lorigan P. Does adjuvant vaccine therapy really have activity in malignant melanoma? J Clin Oncol. 2007;25:4693. author reply 4693–4695

    Article  PubMed  Google Scholar 

  23. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.

    Article  CAS  PubMed  Google Scholar 

  26. Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47:1476–83.

    Article  CAS  PubMed  Google Scholar 

  27. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:1087–95.

    Article  CAS  PubMed  Google Scholar 

  28. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.

    Article  CAS  PubMed  Google Scholar 

  29. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.

    Article  CAS  PubMed  Google Scholar 

  30. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lee CI, Menzies AM, Haydu LE, et al. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Res. 2014;24:468–74.

    Article  CAS  PubMed  Google Scholar 

  34. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.

    Article  CAS  PubMed  Google Scholar 

  36. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17.

    Article  CAS  PubMed  Google Scholar 

  37. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Melanoma and Skin Service and Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    Belinda Lee & Grant A. McArthur MBBS, BMedSc, PhD, FRACP

  2. Univeristy of Melbourne, Parkville, VIC, Australia

    Grant A. McArthur MBBS, BMedSc, PhD, FRACP

Authors
  1. Belinda Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grant A. McArthur MBBS, BMedSc, PhD, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Grant A. McArthur MBBS, BMedSc, PhD, FRACP .

Editor information

Editors and Affiliations

  1. Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Michael S. Hofman

  2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

    Rodney J. Hicks

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Lee, B., McArthur, G.A. (2017). Management of Melanoma. In: Hofman, M., Hicks, R. (eds) PET/CT in Melanoma. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-54741-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-54741-1_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-54740-4

  • Online ISBN: 978-3-319-54741-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation